Get the Stockscreener App
0.7247
0.61%
0.0044
After Hours:
.71
-0.0147
-2.03%
Geovax Labs Inc stock is traded at $0.7247, with a volume of 520.83K.
It is up +0.61% in the last 24 hours and up +49.42% over the past month.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
See More
Previous Close:
$0.7203
Open:
$0.71
24h Volume:
520.83K
Relative Volume:
0.35
Market Cap:
$11.54M
Revenue:
$356.60K
Net Income/Loss:
$-24.32M
P/E Ratio:
-0.0784
EPS:
-9.24
Net Cash Flow:
$-27.24M
1W Performance:
-8.27%
1M Performance:
+49.42%
6M Performance:
-62.06%
1Y Performance:
-65.65%
1-Day Range:
$0.688
$0.7439
1-Week Range:
$0.688
$0.825
52-Week Range:
$0.43
$11.18
Geovax Labs Inc Stock (GOVX) Company Profile
Name
Geovax Labs Inc
Sector
Industry
Phone
678-384-7220
Address
1900 LAKE PARK DRIVE, SMYRNA
Compare GOVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
0.7247 | 18.12M | 356.60K | -24.32M | -27.24M | -9.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Reiterated | Alliance Global Partners | Buy |
| Apr-15-25 | Reiterated | D. Boral Capital | Buy |
| Nov-11-24 | Initiated | Alliance Global Partners | Buy |
| Jul-16-24 | Initiated | ROTH MKM | Buy |
| Nov-19-20 | Initiated | Maxim Group | Buy |
Geovax Labs Inc Stock (GOVX) Latest News
Why is GeoVax Labs Inc. Equity Warrant stock attracting strong analyst attentionWealth Building Opportunities For Beginners - jammulinksnews.com
GeoVax Labs receives Nasdaq notice for non-compliance with minimum bid price - Investing.com Australia
Is it the right time to buy GeoVax Labs Inc. stockBest Dividend Outlook For Consistent Profits - jammulinksnews.com
How does GeoVax Labs Inc. Equity Warrant generate profit in a changing economyAdvanced Screener Entry Points For Consistent Profits - jammulinksnews.com
When is GeoVax Labs Inc. Equity Warrant stock expected to show significant growthReal Time Opportunities Backed By Experts - jammulinksnews.com
Smyrna biotech company chases European approvals amid cash crunchAtlanta Business Chronicle - The Business Journals
How volatile is GeoVax Labs Inc. stock compared to the marketFree Stock Trend Scanner That Work - jammulinksnews.com
Securing the Future: Strategic Investments in U.S. Biodefense and GeoVax's MVA Vaccine Platform - AInvest
GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains - Yahoo Finance
MACD Signals Flash Warning for GeoVax Labs Inc. StockCommunity Strategy With High Win Rate Backtested - beatles.ru
Published on: 2025-07-29 20:26:14 - metal.it
GeoVax Labs Revenue Doubles in Q2 - AOL.com
GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation - NewMediaWire
GOVX: Geovax Labs Maintains "Buy" Rating and $9 Price Target | G - GuruFocus
GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation | Dow Theory Letters - FinancialContent
What caused GOVX's Q2 2024 profit turnaround? - AInvest
What are the latest earnings results for GeoVax Labs Inc.Low Risk Alerts Backed By Experts - jammulinksnews.com
Geovax Labs shares rise 4.73% premarket after Q2 2025 earnings call. - AInvest
GeoVax Labs 2025 Q2 Earnings Misses Targets as Net Loss Widens - AInvest
GeoVax Labs Q2 2025 Earnings Call Transcript - MarketBeat
Geovax Labs Inc (GOVX) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance
GeoVax Advances in Vaccine and Immunotherapy Development with Promising Clinical Data - citybuzz -
GeoVax Labs Inc. Breaks Losing Streak — Is the Trend ReversingOptimized Watchlist With Daily Adjustments Launched - metal.it
GeoVax's 2025 Q2: Unpacking Contradictions in Vaccine Manufacturing and Clinical Trials - AInvest
GeoVax Labs Q2 2025 Earnings Conference Call Transcript - AInvest
Earnings call transcript: GeoVax Labs Q2 2025 sees revenue surge, stock dips - Investing.com Nigeria
GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Published on: 2025-07-28 20:40:12 - metal.it
How strong is GeoVax Labs Inc. Equity Warrant company’s balance sheetWealth Building Trend Scanner That Work - jammulinksnews.com
How does GeoVax Labs Inc. generate profit in a changing economyUnlock exclusive stock market insights - jammulinksnews.com
GeoVax Advances Needle-Free Vaccine Technology with HD-MAP Platform Study - citybuzz -
GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology | Dow Theory Letters - FinancialContent
What are the technical indicators suggesting about GeoVax Labs Inc.Take advantage of unprecedented market momentum - jammulinksnews.com
What are GeoVax Labs Inc. company’s key revenue driversAccess high-quality stock research instantly - jammulinksnews.com
GeoVax to Report Q2 2025 Financial Results and Corporate Update on July 28, 2025 - AInvest
What catalysts could drive GeoVax Labs Inc. Equity Warrant stock higher in 2025Unlock powerful trading tools for investors - jammulinksnews.com
What makes GeoVax Labs Inc. Equity Warrant stock price move sharplyEarly Buy Suggestion - metal.it
How Resilient Is GeoVax Labs Inc. Equity Warrant Stock During Economic DownturnsConsistent High Return Strategy - metal.it
What is GeoVax Labs Inc. Equity Warrant company’s growth strategyRapid portfolio appreciation - jammulinksnews.com
How volatile is GeoVax Labs Inc. Equity Warrant stock compared to the marketDiscover stocks with explosive potential - jammulinksnews.com
Published on: 2025-07-28 04:18:10 - jammulinksnews.com
What is the dividend policy of GeoVax Labs Inc. stockAccelerated capital growth - jammulinksnews.com
Is GeoVax Labs Inc. Equity Warrant Stock a Good Fit for Conservative InvestorsWeekly Double Return List - Newser
How many analysts rate GeoVax Labs Inc. as a “Buy”Maximize your portfolio’s earning potential - jammulinksnews.com
What institutional investors are buying GeoVax Labs Inc. Equity Warrant stockAccelerated investment success - jammulinksnews.com
Geovax Labs Inc Stock (GOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):